Biotech Co. Can't Halt Astellas UPC Fight Amid EPO Challenge
A Japanese biotech company failed to convince the Unified Patent Court to stay a bid from an Astellas Pharma subsidiary to revoke its patent for vision loss treatment until parallel proceedings...To view the full article, register now.
Already a subscriber? Click here to view full article